Osimertinib is a third-generation EGFR-TKL that selectively and significantly suppresses T790M-resistance mutations in lung cancer patients and is approved in the first-line treatment of EGFR-mutant lung cancer (113, 114). This evidence concerns the gene EGFR and lung cancer.